Abstract: The present invention relates to the field of the treatment and/or prevention of viral infection caused by SARS-CoV-2. The inventor found that N-(2(quinolyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone was able to inhibit SARS-CoV-2 replication both in vitro and in vivo and that this inhibition was more important compared to the one obtained with the non-O-methylated form of this compound (quinolyl-valyl-aspartyl-[-2,6-difluorophenoxy]-methyl ketone). Thus the present invention concerns the N-(2(quinolyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone or a pharmaceutically acceptable salt or solvate thereof for use in preventing and/or treating a viral infection caused by SARS-CoV-2. The present invention also concerns a pharmaceutical composition and a kit of parts comprising such a compound for the same use.

Abstract: SARS-COV and SARS-COV-2 share similar pathogenic pathways that interact with pathways of cellular cholesterol metabolism. Depletion of cholesterol from cell membranes reduced the infectivity of SARS-COV by 90%. Several studies reported that pantethine was able to reduce total cholesterol levels and total fatty acids synthesis but its anti-SARS COV-2 activity has never been investigated. The inventors now demonstrate that pantethine is highly effective in the control of SARS-COV-2 infections in vitro. In particular, the inventors show that the effect of pathethine on the inhibition of the replication of SARS-COV-2 is interested at the dose of 100 ?M (inhibition is around 76%) and the most effective concentration is 1000 ?M (inhibition is around 98%). Pantethine treatments were able to reduce significantly the expression of the viral Spike and Nucleocapsid proteins and the accessory proteins ORF6. Thus the present invention relates to the use of pantethine for the treatment of a SARS COV-2 infection.

Abstract: The present invention relates to the use of the compound of formula (I) or its pharmaceutically acceptable salts, in the prophylaxis and/or treatment of a viral infection. It also relates to an antiviral composition comprising or consisting of at least the compound of formula (I) or one of its pharmaceutically acceptable salts, and at least one other antiviral agent; and to products comprising or consisting of at least the compound of formula (I) or one of its pharmaceutically acceptable salts, and at least one antiviral agent, as a combined preparation for simultaneous, separate or sequential use in antiviral therapy; or for simultaneous, separate or sequential use for the prophylaxis and/or treatment of a viral infection.

Abstract: A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxyl)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.

Abstract: A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxyl)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.

Abstract: A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.

Abstract: A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.

Abstract: The invention which is the subject of the present application relates to a compound of structure I: A-B-C for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or a quinoline-type group, B is a single amino acid or a peptide or polypeptide having a given amino acid sequence, C is an O-phenoxy group and the symbol “-” indicates that the entities A, B and C are chemically bonded within the compound I. According to a particular embodiment, said compound is a protease inhibitor, in particular a caspase inhibitor, and more particularly the inhibitor Q-VD-OPh (N-(2(quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone), optionally in an O-methylated form.